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Summary A study of activation of the cytokine network by interleukin 2, IL-2, may provide a rationale for
devising cytokine combination and cytokine antagonist treatments with increased anti-tumour efficacy and
decreased toxicity. We have investigated the expression of mRNA for 13 cytokines and three transcription
factors during in vitro culture of peripheral blood mononuclear cells, PBMC, with IL-2. A consistent pattern
of induction was seen in nine individuals, with early (2-24 h) induction of IL-1p, IL-6, tumour necrosis factor,
TNF, lymphotoxin, LT, and gro. TNF and LT mRNA was expressed continually throughout culture, but
levels ofmRNA for IL-1p, IL-6, and gro declined by 24-48 h. After 48 h, PBMC began to express mRNA for
IFN-y, IL-5, GM-CSF, and M-CSF. At 15 min to 1 h post IL-2 mRNA for c-fos, c-jun, and c-myc, and TNF
was induced in three individuals studied. IL-4, IFN-a, and IL-la mRNA was not detected. Only a minority of
cells expressed mRNA for TNF, IL-1,. IL-6 and IFN-7, and monocytes were the main source. Levels of
cytokine protein in culture supernatants mirrored the pattern of mRNA induction. This in vitro model shows
clear parallels with the reported in vivo production of cytokines during IL-2 therapy, and may prove useful in
designing new therapeutic strategies.
Therapy with IL-2, with or without ex vivo activated lym-
phocytes, has resulted in partial, and occasionally complete,
tumour regressions in a minority of patients with melanoma
and renal cell carcinoma (Dutcher et al., 1989; Negrier et al.,
1990). The induction of cytolytic activity in peripheral blood
mononuclear cells, PBMCs, by IL-2 has been well docu-
mented both in vitro and in vivo (Grimm et al., 1982; Rosen-
berg et al., 1985). The mechanisms of activation of this
heterogeneous population of cells are not fully elucidated.
Several studies have shown that in vitro activation results in
production of several cytokines. Early (24h) induction of
IL-la and IL-1B mRNA has been reported, as has the induc-
tion of TNF, LT and IFN-7 mRNA (Kovacs et al., 1989). In
other studies mRNA for GM-CSF and IL-6 was detected in
PBMC after 3 days of culture with IL-2 (Belldegrun et al.,
1989; Kasid et al., 1989).
The study of cytokines induced by IL-2 in vitro and in vivo
is important for several reasons. First, these secretory pro-
ducts may contribute to the antitumour effects of IL-2 in
vivo. Cytokines such as TNF and IFN-y have well docu-
mented antitumour activity in animal models (Kelly et al.,
1989), and synergy between IL-2 and other cytokines has
been reported (Truitt et al., 1989). Second, the toxicity of
IL-2 therapy may be related to the cytokines released by
activated PBMC. For instance, anti-TNF antibody abrogated
some of the toxic side effects of IL-2 in tumour bearing mice
(Fraker et al., 1989), and antibodies to IL-S abolished the
IL-2 induced eosinophilia in mice (Yamaguchi et al., 1990).
Third, studies ofcytokine induction in a mixed population of
mononuclear cells also gives us indications of the range of
cytokines which may be induced after other mitogenic or
antigenic stimuli.
In order to understand the potential of other cytokines or
their antagonists, for influencing the anti-tumour activity or
toxicity of IL-2 in humans, we have studied in detail the
range and temporal sequence of cytokine mRNA and pro-
teins induced by IL-2, and the producer cells of those cyto-
kines. In this paper we present data obtained in in vitro
cultures of human PBMC with IL-2.
Materials and methods
Reagents
Human rIL-2 was generously supplied by Glaxo IBM
(Geneva, Switzerland) (specific activity 3.1 x 106U mg-'),
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and Roussel-UCLAF Centre de Recherche (Romaine, France)
(specific actitivity 106 U mg-'). Maximum cytotoxicity was
induced when the cells were cultured with 000 U mg-' of
IL-2.
Preparation ofPBMCs
Peripheral blood mononuclear cells from healthy donors
were separated from heparinised venous blood on Ficoll-
Hypaque gradient (Lymphoprep TM, Nycomed Pharma AS,
Oslo, Norway). The cells were resuspended at 1 x 106 ml-' in
RPMI 1640 containing 10% heat inactivated foetal calf
serum with or without 1000 U ml rhIL-2. Cellular cytotoxi-
city was assayed after 3 days of culture. For northern blot
analysis cells were lysed with guanidine-isothiocyanate solu-
tion for RNA extraction. For in situ hybridisation cells were
immunostained for FACS sorting.
Cell lines aspositive controlsfor Northern blot analysis
The HL60 human promyelocytic leukaemic cell line was
maintained in 5% FCS/RPMI 1640. Total cellular RNA was
extracted after a 3 h incubation with 50 ng ml-l PMA
(Sigma, Dorset, UK). This constituted a source of TNF,
IL-lo, IL-1p, M-CSF, and TGF-P mRNA as a positive con-
trol for Northern blot analysis. Human T-cell line Jurkat
cells were stimulated overnight with 1 ng ml-' phytohaemag-
glutinin (Sigma, Dorset, UK) and 20 ng ml-' PMA. Ex-
tracted RNA provided a positive control for IFN-'y. Human
foreskin fibroblasts were stimulated with 10 ng ml-' PMA
for 1 h, providing a positive control for IL-6 mRNA. MLA-
144 T cell line stimulated with PHA and PMA provided a
positive control for GM-CSF mRNA. It was not possible to
obtain reliable controls for IFN-a and IL-4 expression using
Northern analysis however the INF-a factor reacted on a
Southern blot.
Labelling oftarget cells
Freshly thawed T 24 cells were washed three times in com-
plete medium. 0.1 mCi of 5"Cr (Na251CrO4) (Amersham Inter-
national UK) was added to the cell pellet. Cells were
incubated at 37°C for 1 h, then washed in complete medium
three times to remove unbound 5"Cr. Cells were resuspended
in medium at a final concentration of 5 x 104ml-'.
Isolation ofcellular RNA
Non-adherent cells from PBMC cultures were harvested. The
adherent cells were scraped with rubber policeman into
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guanidine-isothiocyanate solution which was then used to
lyse the non-adherent fraction. Total cellular RNA was
isolated after centrifugation through cesium chloride followed
by precipitation with 3 M sodium acetate and ethanol (Chirg-
win et al., 1979).
Northern blot analysis
Fifteen tLg aliquots of total cellular RNA were electro-
phoresed through a 1.4% agarose-formaldehyde denaturing
gel then capillary blotted onto Biodyne A membrane (Pall
Ultrafine Fifteration Corp., Glen Cove, NY). Membrane
were hybridised to 32P-labelled inserts of human complemen-
tary DNA probes under standard conditions as outlined by
Church and Gilbert (1984) and labelled with [32P]dCTP
(Amersham International UK) by the random priming
method of Feinberg and Vogelstein (1984). Membranes were
subsequently washed to high stringency and exposed to
Kodak XAR5 film at - 70°C with two intensifying screens
(Dupont, Stevenage, Herts, United Kingdom). Films were
exosed for 7 days.
In situ hybridisation
The technique used was essentially as described in Naylor et
al. (1990) except that no prehybridisation stages were needed
with cytospins. 10pl of the hybridisation buffer containing
35S-labelled RNA probe at 5 x 0I dpmfl-1, was added to
each slide, which was then covered with a siliconised cover-
slip and left to hybridise at 50°C for 16 h. Slides were washed
to high stringency at 50°C for 30min, then 65°C for 16 h.
Slides were washed to high stringency at 50°C for 30 min,
then 65°C, followed by RNAse treatment to digest the un-
bound RNA followed by autoradiography. Slides were devel-
oped after 10 days of exposure and stained with methylene
blue.
Probes
For Northern analysis The following probes were used:
TNF: PstI fragment of p-hTNF 1; IFN-y: BamHI fragment
of pBR327gO-2; IL-la: HindIII-EcoRI fragment of pSPhIL-
la.2; IL-lb: HindIII fragment of pSPhL-1P.2; IL-6: BglII
fragment of pSP65T-IL-6; TGF-Pxw EcoRI fragment pbas
TGF-P1 (Genentech, California); P-actin: EcoRI-Hindlll
fragment of M13 P-actin; IL-5: XbaI-BamHI fragment of
pGEM4 IL-5; M-CSF: PstI-SmaI fragment of pUC18 M-
CSF; GM-CSF: HXhI fragment of pXM GM-CSF; Gro:
geneEcoRI fragment of pGEM3 Gro; IFN-oa: EcoRI frag-
ment of PIF 211-hIFN-a2 (Wellcome, Beckenam, Kent, UK);
LT- HindIII-PVUII fragment of pOKBLT-6-hLT; IL-10:
cDNA clone (Vieira et al., 1991). c-myc: BamHI-SalI frag-
ment of DOR h-c-myc; c-jun: EcoRI-BamHI fragment of
M13 c-jun; fos: BglI-PvuII fragment of pFBH-1-fos; ras:
EcoRI fragment of pBR322 ras-Ha (Dhar et al., 1982).
For in situ hybridisation An antisense P-actin riboprobe was
generated from HindIII cleaved Bluescript M13 IB-actin using
T7 RNA polymerase. This was used as a positive controls in
all runs. Antisense TNF was generated from the ApaI
cleaved pGEMI-hTNF using T7 RNA polymerase (Promega
Biotech, Madison WI). The negative control was sense TNF
generated from BamHI cleaved pGEM-hTNF using Sp6
RNA polymerase (Promega, Biotech). The antisense IFN-y
riboprobe was generated from ApaI cleaved pGEM-3 using
T7 polymerase, the sense control was generated from EcoRI
cleaved pGEM-3 using Sp6 polymerase. Antisense IL-1p
riboprobe was generated from EcoRI linearised pSP h IL-1-
P.2 Antisense IL-6 riboprobe was generated from AccI line-
arised pGEM-3 using T7 polymerase, sense control from
XbaI linearised pGEM-3 using Sp6 polymerase. In vitro
transcriptions were performed using Promega Biotech trans-
cription kits to incorporate 3"S-UTP (Amersham Interna-
tional plc, UK). Restriction enzymes were obtained from
Pharmacia.
Flow cytometry and cellsorting
On days 1 and 4 of culture in the presence or absence of
IL-2, aliquots of PMBC were stained by direct immuno-
fluorescence following the standard procedure recommended
by the supplier of the fluorescent conjugates (Becton Dickin-
son Immunocytometry Systems, San Jose, Ca, USA). Non
adherent and adherent cell populations were pooled for the
analysis, adherent cells being removed from the culture by
rubber policeman after incubation on ice for 1 h. Cells were
labelled with either (a) anti-Leu-M3/phycoerythrin (PE) (CD-
14), (b) Simultest anti-Leu-4/FITC (CD3) + anti-Leu-1IC/PE
(CD16) + anti-Leu-19/PE (CD56) or (c) Simultest anti-Leu-
3a/FITC (CD4) + anti-Leu-2a/PE (CD8). All samples were
examined using a FACStarPLUS (Becton Dickinson
Immunocytometry Systems) and relevant populations sorted.
The sorted populations were then recycled through the FAC-
StarPLUs to ensure a high degree of purity. The flow cyto-
meter was flushed with 0.1% diethylpyrocarbonate in
phosphate buffered saline for 2 h prior to sorting. The col-
lected cells were centrifuged at 1000 r.p.m. for 5 min at 4°C
resuspended at a concentration of 1 x 106 cells ml-'.
Preparation ofslides
Sorted cells were then spun onto slides using a Shandon
Cytospin centrifuge (Shandon Scientific Ltd., Astmoor, Run-
coon, UK) at 500 r.p.m. x 5 min. Slides were then fixed in
4% paraformaldehyde (Sigma, Dorset, UK) in phosphate buffered saline, alcohol dehydrated and stored at - 70°C.
Cytokineprotein assays
IL-1p--was measured using EASIA kit from Medgenix (Brussels, Belgium) with a range of 33-1400pgml-'. It was
standardised against an international reference preparation (86/680) from the National Institute of Biological Standards
and Controls, NIBSC, and was used at detection limits of
33 pg ml'. TNF-o and IFN-y were measured using IRMA
kits from Medgenix (Brussels, Belgium). The TNF-a IRMA
range was from 15-5000 pg ml-'. It was standardised against
an international reference preparation (87/650) from the
National Institute of Biological Standa'rds and Controls, NIBSC, and was used at detection limits of 30 pg ml-'. The
IFN-y-IRMA range was from 0-90 U ml-'. It was standar-
dised against an international reference preparation (88/606) from NIBSC and was used at detection limits of 2.5 U ml-'.
The IFN-a was measured using RIA kits from Medgenix (Brussels, Belgium). The range was from 0-200 U ml-'. It
was standardised against an international reference prepara- tion (82/576) from NIBSC and was used at detection limits
of 8.0 U ml'. IL-6 was an 'in house' RIA (antisera G150
BM from Dr S. Poole, NIBSC). The antisera was used at a
final dilution of 1:1,750,000 (equivalent to an initial dilution
of 1:350,000). The assay was standardised against an interna-
tional reference preparation (88/514) from -NIBSC and was
used at detection limits of 70pg ml-'.
Results
Induction ofcytokine andproto-oncogene mRNA in IL-2
stimulated cultures-Northern analysis
In the first series of experiments we studied the induction of
mRNA for 13 different cytokines in PBMC stimulated with
10,000 U ml-' IL-2, a concentration of IL-2 that generated maximal in vitro cytotoxicity against T24 cells. Table I and
Figure 1 show the results obtained in cultures from one
normal individual. In the interests of clarity, Table I only shows the mRNA induction in IL-2 stimulated cultures. The
figure, however, clearly shows that there was no appreciable induction ofcytokine mRNA in the cultures without IL-2. In
this first individual, there were three different patterns of
cytokine induction: TNF and LT were detected as early as
2 h after IL-2 addition and the mRNA was then present516 K.A. SARAYA et al.
Table I Summary of Northern blot analysis of cytokine mRNA
induction in PBMC cultured with or without IL-2
Time C 2h I d 2d 3d 4d 5d 6d 7d
mRNA
TGF-P + + + + + + + + +
TNF - + + ++ ++ + + + +
LT - + + + + + + + +
Gro - + ++
IL-lp - + ++ + + - - - -
IL-6 - ++ - + - -
IL-5 - - - + + + + + +
IFN-y - - - + ++ ++ ++ + +
GM-CSF - - - - ++ + + + +
M-CSF - - - - + + - - -
IFN-a - - - - - -
IL-la - - - - - -
IL-4 - - - - - - - - -
P-actin + + + + + + + + +
Exp. no. 1 (h = hour, d = day) (+) indicates the intensity of
mRNA induction within each individual case. In this experiment, all
time points were studied without IL-2 but only one representative
time point is shown as (C).
throughout the 7 days of culture; IL-1,, IL-6 and the gro
gene (a member of the intercrine family, related to IL-8) were
also induced 2 h after stimulation, but their induction was
only transient, and none of these were detected after 3 days
of culture; IL-5, IFN-'y, GM-CSF, and M-CSF were induced
at a later time, being first present at 2-3 days. Expression
was then sustained throughout the culture period in all of
these except M-CSF. mRNA for IFN-a, IL-la, and IL-4
were not detected during this time. TGF-P mRNA was pre-
sent in all cultures, stimulated or unstimulated (data not
shown).
This pattern of cytokine gene expression during culture of
PBMC with IL-2 was found to be reasonably consistent in
PBMC from another eight individuals who were studied
(Table II). TNF and IL-lp were induced in PBMC from 8/8
individuals, LT, gro, IL-6, GM-CSF, IFN-y and M-CSF
were induced in 4/4 studied. IL-5 mRNA was only detectable
in PBMC from 1/4 individuals studied but was also expressed
in the unstimulated culture from that individual, and IFN-x
and IL-4 were again not found. A probe for IL-10 was also
included in this series. In one individual IL-10 mRNA was
induced in unstimulated cells after 24 h of culture. The inten-
sity of the message started to decline during the first 2 days
Time points 2 h 1 d 2d 3d 4d 5d 6d 7d _+ -+ -+ + -+ -+ + -+
mRNA
TNF
LTll__l
....~~~~~~~~~~~~~~~~~~~..
Gro gene
IL-6
IL-5
IFN-y
GM-CSF
M-CSF
..... .....
IL-4 _
IFN-cx
IL-la.
......
f3-actin
Figure 1 Northern blot analysis of cytokine mRNA in PBMC. Total cellular RNA isolated from unstimulated PBMC (-), or
IL-2 stimulated PBMC (+) at the given time points (expt. 1) (h = hours, d = days).CYTOKINE INDUCTION BY IL-2 517
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of culture with IL-2 and was not detected at later time points
(Figure 2).
In a third series of experiments, the induction of nuclear
proto-oncogenes and two of the cytokines, TNF and gro, was
studied during the first hour after IL-2 stimulation. There
was evidence of a transient increase in c-myc levels at 15 min
in 2/3 individuals,fos was induced in all three individuals at
15 min, gro gene was induced at 30-60 min, and TNF
mRNA induction was seen as early as 30 or 60 min. There
was no detectable mRNA for Ha-ras (Table III).
Cellpopulations in IL-2 stimulated cultures
The proportion of monocytes (CD14), T cells (CD3), NK
(CD16/CD56), and cells coexpressing NK/CD3 markers,
were studied in IL-2 stimulated PBMC cultures. No signifi-
cant changes were seen in the relative proportions of these
populations after 4 days culture with or without IL-2, in
PBMC from five out of six individuals. In the unstimulated
cultures the mean % T cells was 70 (±+ 11) of total cell count,
NK cells 4 (± 4)% and cells coexpressing NK and CD3
markers 2 (± 3)%. After IL-2 stimulation the mean percent-
age of T cells was 74 (± 7), NK cells 5 (± 4)% and cells
expressing NK and T cell markers 3 (± 3)%. In one case the
number of cells coexpressing T and NK cell markers rose
from 8% of the total population in unstimulated cultures to
76% of the IL-2 stimulated cultures. The percentage of
CD14 + ve monocytes after 4 days of culture was 10% (± 1)
in unstimulated cultures and 9% (± 1) in IL-2 stimulated
cultures.
Identification ofcellsproducing the cytokine mRNA
Using FACS sorting and in situ hybridisation with cytokine
riboprobes, we identified the producer cells of four different
cytokines, TNF, IL-1p, IFN-y, and IL-6 in the total popula-
tion and the sorted cells. These cytokines were studied at the
time of peak message induction in the Northern blots, in
three individuals. The proportion of cells in the total popula-
tion with detectable cytokine mRNA ranged from 2-16%
after 1 day of culture for IL-6 and IL-1,B, and 4 days of
culture for IFN-y and TNF. As a control for cytokine
mRNA stability during FACS sorting, the total PBMC
population was passed through the sorting process and the
percentage of cells expressing cytokine mRNA compared to
that in cells cytospun at the beginning of this process. No
differences were seen. Because of the small numbers of cells
involved in these experiments, the gated populations were
resorted to ensure high degrees of purity. Resorting of cells
likewise did not affect mRNA stability.
IL-Jp In two of the three individuals, 2-3% cells in the
total population expressed IL-1p mRNA. These cells were
monocytes, and in sorted populations 8-35% of monocytes
expressed IL-l1 mRNA. In cells from a third individual,
IL-1lB mRNA was induced in 19% of monocytes, 6.6% of
NK cells, 3% CD4 + and 8% CD8 + cells on IL-2 stimula-
tion, making a total of 16% expressing cells in the total
population. In the unstimulated control cultures a small pro-
portion of monocytes and CD8 + cells expressed IL-1p
mRNA (0.1-0.5% and 0.2% of the total population respec-
tively).
IL-6 In the three individuals 0.4-6% of the total cells
expressed IL-6 mRNA after 24 h stimulation with IL-2. In
two out of three cases IL-6 mRNA was detected in the
monocyte (2-6% monocytes positive) and NK (1-4% cells
positive) populations. In the third case IL-6 mRNA was
detected only in monocytes (22% positive).
IFN-7 Between 2 and 5% of the total cell population ex-
pressed IFN-y mRNA. IFN-y mRNA was detected in all
sorted populations except the CD8 cells. NK (6-13% cells
positive) and CD4 cells (2-3% positive) made a significant
contribution to levels of mRNA in the total population, but,
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1 d 2h 1 d 2d
Time points - + + +
4d 4d 7d
_ + +
IL-10 mRNA
Figure 2 Northern blot analysis of IL-10 mRNA expression in PBMC cultured with or without IL-2. Cells from exp. 6 were lysed
at the indicated time points (h = hours, d = days) for RNA isolation. (-) without IL-2 (+) with IL-2.
Table III Induction of transcription factors and cytokine mRNA in PBMC during the first hour of culture with or
without IL-2
Exp. 10 Exp. 11 Exp. 12
C 5' 15' 30' 60' C 5' 15' 30' 60' C 5' 15' 30' 60'
C-myc + + + + + + + + + + + + + + + + +
C-jun + + + + + + + + + + + + + + + + + + + +
fos - - + + + - + + + + - - + + + _ _
gro - - + + ++ + + + ++ +++ + + + ++ ++
ras -
TNF - - - - + - - - + ++ _ _ _ _ +
(+) indicates the intensity of mRNA induction within each individual case. RNA from cells cultured without IL-2 (C)
was analysed at 30 and 60min with identical results.
interestingly, in all three individuals 3-4% of monocytes
expressed IFN-y mRNA on IL-2 stimulation. No IFN-'
production was detected in unstimulated control cultures.
Figure 3 shows results from in situ hybridisation of the sense
and anti-sense IFN-y riboprobes in total population and
NK/CD3 populations in one individual.
TNF Between 1 and 3% of cells in the total population
expressed TNF mRNA. These were 4-5% of the monocytes
population and 1-3% of the CD3 cells. TNF mRNA was
also detected in a small minority (0.1%) of monocytes from
unstimulated cultures.
Production ofcytokine protein
Cytokine protein levels were measured in the culture fluids
from eight different experiments by immunoassay. The results
are shown in Figure 4.
IL-1p The production of IL-1p in the IL-2 stimulated cul-
tures was maximal in the first 2 days of culture. The IL-lp
concentration varied from 90 pg ml-' to 1300 pg ml-'. In
unstimulated cultures it peaked at lOOpgml-'.
IL-6 IL-6 protein concentration peaked maximally after
2-4 days of culture with IL-2, occurring after the first
Figure 3 In situ hybridisation of an 35S labelled IFN-y riboprobe to IL-2 stimulated PBMC after 4 days of culture. a, Antisense
IFN-y riboprobe hybridised to total population of cultured cells. b, Sense IFN-y riboprobe hybridised to the same population. c, Antisense IFN-y riboprobe hybridised to FACS sorted cells co-expressing NK and CD3 marker. d, Sense IFN-y riboprobe
hybridised to the same population.CYTOKINE INDUCTION BY IL-2 519
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Figure 4 Mean concentration of cytokine proteins as measured by immunoassays in culture supernatants of PBMC. Control
(-IL-2) samples were collected at day 1 and 4. The results shown are the mean of the values from cultures from eight different
individuals. * = with IL-2 -- --= without IL.2.
evidence of IL-6 mRNA induction. In one of seven un-
stimulated cultures, the spontaneous production of IL-6 pro-
tein was at a level (3029pgml-') comparable to the IL-2
stimulated culture. In the other unstimulated cultures IL-6
concentration ranged between 0-1206. After IL-2 stimula-
tion, the maximal concentration ranged from 2903-
3512 pg ml'.
IFN-y Maximal production of IFN-y protein by IL-2 stimu-
lated PBMC was invariably found at 4 days of culture. The
maximum IFN-y concentration varied from 28-90IUml1'.
No spontaneous production was detected in the unstimulated
culture supernatants. The pattern of protein production
matched exactly IFN-y mRNA induction.
TNF Maximum levels of TNF were detected at 4 days of
culture, in seven experiments and at 7 days in one experi-
ment. Spontaneous production occurred one out of six cul-
tures (1100 pg ml-'). The TNF concentration in control
cultures was 30-1100 pg ml-', while maximal production on
IL-2 stimulation ranged between 5,300-10,000pgml-'.
Discussion
Previous in vitro and in vivo human studies have reported the
induction of IL-1, TNF, LT, IFN-y, IL-6 and GM-CSF
mRNA in IL-2 stimulated PBMC but there has been little
information on the time course of induction or cellular origin
of these mRNA. In this paper we show that PBMC incu-
bated in vitro with IL-2 produced a wide range of cytokine
mRNA. IL-1p, TNF, LT, gro gene, and IL-6 mRNA were
induced early in the culture (30 min-2 days). Later in culture
IFN-'y, IL-5, M-CSF and GM-CSF mRNAs were induced.
The induction was transient in some of the cases and persist-
ent in others. The temporal pattern of cytokine mRNA
induction was consistent among individuals. Within limits of
detection of the assay mRNA for IL-la, IL-4 and IFN-x
were not found. This does not preclude their production as
indicated by the results of the assay for TNF protein. TNF
mRNA in cultures without IL-2 was generally undetectable,
but in some cases the protein was found in the cultures.
In at least four of the cytokines, TNF, IL-1p, IFN-y and
IL-6, the production of the protein mirrored the expression
of mRNA. Previous in vitro studies reported the production
of Il-lm and P proteins in culture supernatants of II-2 stimu-
lated PBMC (Numerof et al., 1989).
In situ hybridisation studies on FACS sorted PBMC
revealed that the monocytes were the main producers of the
above mentioned cytokines, but the NK cells shared in the
production of IL-6 and IFN-y, while the CD4 + cells pro-
duced IFN-y as well. At each given time point only a small
percentage of cells in The total or in the sorted population
was positive for each cytokine mRNA. This low figure may
influence any firm conclusions as to the cellular source of the
cytokines. However, each gated population was resorted in
each experiment, and this resulted in high (<95%) purity.
We do not think the low level of positivity is due to limits of
detection of this technique because a high percentage of
positive cells was seen in controls incorporated in each
experiment. PMA induced HL60 cells were used as positive
controls for TNF, IL-P and IFN-y mRNA, PMA induced
HFF cells were used for IL-6 mRNA induction. More than
90% of cells counted were positive for the relevant mRNA.
In addition, control experiments proved that the low percent-
age was not due to instability of RNA during the sorting
process, as described in the Results section.
The production of cytokines by the monocytes is unlikely
to be due to a direct effect of IL-2 on the monocytes. These
cells express the IL-2Ra subunit of the I1-2 receptor only
when activated (Waldmann, 1991). It is more likely that an
intermediary molecule, possibly one of the other cytokines
induced early on, is responsible for the monocyte cytokine
production. A more detailed study using in situ hybridisation
at earlier time points would be of interest, as would study of
in situ production of some of the other cytokine mRNAs
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identified in the Northern blots. The expression by
monocytes of mRNA for one of the cytokines, IFN-y, is not,
to our knowledge a common finding, although murine mac-
rophages have been reported to produce IFN-y after stimula-
tion with polyinosinic-polycytidilic acid (Djeu et al., 1979).
The beta chain of the IL-2 receptor is expressed on 90%
freshly isolated monocytes (Espinoza-Delgado et al., 1990),
but the alpha chain only on IFN-y activation (Waldmann,
1991). This again suggests that intermediatory cytokines, or
other factors, produced by lymphocytes, act as a stimulus for
IFN-y mRNA expression in these cultures. It is not however
certain whether monocytes in the cultures can produce IFN-y
protein. We are currently investigating this.
Early induction of the cytokines by IL-2 suggests that they
might share in the generation of cytolytic activity of PBMC,
particularly as certain cytokines when added exogenously to
culture, have been found to synergise with IL-2. TNF en-
hanced the cytolytic function in PBMC by IL-2, possibly
through the induction of high affinity IL-2 receptor complex
(Blay et al., 1989), and high serum levels of TNF have been
correlated with response to therapy in one clinical study
(Blay et al., 1990).
The production of IFN-y by IL-2 stimulated PBMC in vivo
might induce the expression of class I MHC antigen on
tumours thus assisting the CTL cytolytic function (Dustin et
al., 1986). This function might be helped by TNF which
induces the expression of the same antigen (Weber &
Rosenberg, 1990). IFN-y might also induce tumour antigen
on tumour cells thus helping the non-MHC restricted
cytotoxicity (Imai et al., 1981).
IL-lp was detected in supernatants of IL-2 stimulated
PBMC, and its exogenous addition to the culture synergised
with IL-2 (Crump et al., 1989). IL-lp exerts a cytotoxic effect
on its own (Gaffney & Tsai, 1986). It was found to induce
gro gene a finding that was specifically associated with the
anti-mitogenic effect of IL-1 (Rangnekar et al., 1991). Gro
gene mRNA was detected in PBMC early in culture with
IL-2. It might be IL-1 induced, and may as well share in the
cytotoxic activity.
IL-6 also synergises with IL-2 stimulating PBMC (Gal-
lagher et al., 1990). It was found to enhance of pore forming
protein gene expression, and is essential, and is essential for
the cytolytic T cell function in humans (Smyth et al., 1990;
Galandrini et al., 1991). IL-6 was found to have antiumour
activity in tumour bearing mice (Mule et al., 1990).
In a murine model IL-5 enhanced IL-2 induced cytolytic
activity in murine splenocytes (Aoki et al., 1989). While in
humans, the eosinophilia observed in patients receiving IL-2
therapy might very well be related to the production of IL-5.
In the murine model mRNA expression of IL-5 in IL-2
stimulated murine splenocytes both in vivo and in vitro corre-
sponded with the occurrence of eosinophilia (Yamaguchi et
al., 1990). Pisani et al. (1991) measured IL-5 levels in serum
of patients treated with IL-2 and reported the elevation of
serum concentration of IL-5. In another study intrapleural
administration of IL-2 in patients with malignant effusion
resulted in an influx of eosinophils (Nakamura et al., 1990).
The cause of IL-2 induced toxicity remains unknown. The
most significant problems are cardiovascular with hypoten-
sion, renal failure, fluid retention and a capillary leak syn-
drome. It has been suggested that TNF and IFN-y contribute
to the toxic effects (Kohler & Sondel, 1989). Passive
immunisation against TNF by antibodies increased the
number of doses of IL-2 that could be given to mice before
fatal toxicity (Fraker et al., 1989).
C-fos and c-myc genes and their relevant proteins, exert a
role in cellular activation (Kaczmarek & Kaminiska, 1989)
and together with c-jun are part of the regulatory network of
gene expression (Bertani et al., 1989). The induction of
cytokine mRNA may be dependent on the induction of these
genes and their relevant proteins. We are currently studying
the role of protein synthesis in these effects.
The detection of IL-10 (cytokine synthesis inhibitory fac-
tor) mRNA in one of the cases suggests an autoregulatory
function. IL-lO mRNA was expressed in unstimulated PBMC
and declined in IL-2 stimulated PBMC. IL-10 downregulates
the induction of other cytokines (IL-1, IL-6, IL-8, TNF,
GM-CSF, G-CSF) and exerts an autoregulatory function on
its mRNA induction in LPS stimulated monocytes (De Waal-
Malefyt, 1991).
Recent clinical studies have suggested that this simple in
vitro model may help in understanding the activation of the
cytokine network in patients treated with IL-2, and in design-
ing trials with cytokine combinations. For instance, List et al.
(1992) found transient induction of TNF, IL-lp, IL-6, and
IFN-'y in the cerebrospinal fluid of patients receiving IL-2 by
the intraventricular route. In other clinical studies, blood
from IL-2 treated patients has been reported to contain IL-6,
TNF and IFN-y (Schaafsma et al., 1991; Boccoli et al., 1990)
and using PCR mRNA for M-CSF, GM-CSF, IL-3, and
IL-5 was detected in PBMC form IL-2 treated patients
(Schaafsma et al., 1991). The sequence of release of these
cytokines resembled that seen in cultured PBMC, with the
exception of IFN-y which was released earlier in vitro com-
pared with in vivo (e.g. List et al.). However, it is probable
that other cell populations may be able to respond to IL-2 or
cytokines induced during its use in vivo. Although IL-2 recep-
tor expression is thought to be restricted primarily to
haemopoietic cells, there are reports that some tumour cells
will respond directly to IL-2 (Saachi et al., 1990). Moreover,
tumour cells may well respond to cytokines induced by IL-2
tumour infiltrating lymphocytes.
In summary, IL-2 induced the mRNA of ten cytokines in
PBMC in vitro which might reflect the in vivo release of
cytokines during IL-2 therapy. These cytokines are likely to
contribute to the therapeutic and the toxic effects of IL-2 in
patients. Studies such as these may help rationalise the use of
submaximal doses of cytokines or specific cytokine inhibitors/
binding proteins to obtain a final combination with greater
or equivalent therapeutic efficacy and less toxicity.
We wish to thank Parames Thavasu for excellent technical assistance
with the assays for cytokine protein, and Mr Andrew Edwards and
his colleagues in the Flourescent Activated Cell Sorter Laboratory.
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